As part of the lawsuit filed in federal court in Manhattan, the New York Yankees third baseman made public Saturday's 33-page decision by arbitrator Fredric Horowitz, who shortened a penalty originally set at 211 games last August by baseball Commissioner Bud Selig for violations of the sport's drug agreement and labor contract.
Horowitz, who technically chaired a three-man panel that included a representative of MLB and the union, trimmed the penalty to 162 games, plus all postseason games in 2014.
"While this length of suspension may be unprecedented for a MLB player, so is the misconduct he committed," Horowitz wrote.
Rodriguez in his suit claimed the Major League Baseball Players Association "completely abdicated its responsibility to Mr. Rodriguez to protect his rights" and "this inaction by MLBPA created a climate in which MLB felt free to trample" on Rodriguez's confidentiality rights.
Rodriguez asked for the court to find MLB violated its agreements with the union, that the union breached its duty to represent him and to throw out Horowitz's decision.
The three-time AL MVP five years ago admitted using performance-enhancing drugs while with Texas from 2001-03 but has denied using them since. MLB's investigation of Biogenesis of America, a Florida anti-aging clinic, was sparked after the publication of documents last January by Miami New Times.
Anthony Bosch, the clinic's head, agreed in June to cooperate with MLB's investigation, and Rodriguez's lawyers attacked his credibility because of that agreement, which included reimbursement for the costs of lawyers and security.
"The benefits accorded to Bosch under that arrangement did not involve inducements that the panel considers to be improper," Horowitz wrote.
Horowitz concluded Rodriguez used testosterone, human growth hormone and Insulin-like growth factor-1 in 2010, 2011 and 2012 in violation of baseball's Joint Drug Agreement.
"Direct evidence of those violations was supplied by the testimony of Anthony Bosch and corroborated with excerpts from Bosch's personal composition notebooks, BBMs (Blackberry messages) exchanged between Bosch and Rodriguez, and reasonable inferences drawn from the entire record of evidence," Horowitz wrote.
Horowitz said Rodriguez was introduced to Bosch by A-Rod cousin Yuri Sucart, who knew Bosch through Jorge "Oggi" Velazquez.
"Contrary to the claim of Rodriguez, the challenges lodged to the credibility of Bosch's testimony do not effectively refute or undermine the findings of JDA violations," the arbitrator wrote.
Horowitz concluded MLB was justified in citing violations of the collective bargaining agreement because Rodriguez "played an active role in inducing Bosch to issue his own public denial on Jan. 29" and "attempted to induce Bosch to sign a sworn statement on May 31" saying he never supplied the player.
Rodriguez did not testify in the grievance, walking out after Horowitz refused to order Selig to testify.
In determining the length of the penalty, Horowitz cited a 2008 decision in a grievance involving Neifi Perez in which arbitrator Shyam Das ruled "separate uses are subject to separate disciplines." He said under the discipline system for positive tests, Rodriguez would be subject to at least 150 games for three violations of 50 games. But Horowitz thought Selig's initial penalty was too severe.
"A suspension of one season satisfies the structures of just cause as commensurate with the severity of his violations," he wrote.
Horowitz rejected Rodriguez's argument that the lack of a positive test was proof of innocence.
"It is recognized Rodriguez passed 11 drug tests administered by MLB from 2010 through 2012. The assertion that Rodriguez would have failed those tests had he consumed those PES as alleged is not persuasive. As advanced as MLB's program has become, no drug-testing program will catch every player," Horowitz wrote.
In Selig's notice of discipline to Rodriguez on Aug. 5, he said MLB actively is investigating allegations he received banned substances in 2009 from Dr. Anthony Galea, who pleaded guilty in 2011 to a federal charge of bringing unapproved drugs into the United States from Canada.